Treating Ovarian Cancer With Niraparib: The NOVA Trial

FDA D.I.S.C.O.: Niraparib in Ovarian CancerПодробнее

The PARP Revolution: How PARP inhibitors are changing the landscape of ovarian cancer treatmentПодробнее

PARP inhibitors in ovarian cancer: Clinical updates from SGO 2023Подробнее

Case 1: Use of Niraparib in Ovarian CancerПодробнее

Management of Niraparib Dosing in Ovarian CancerПодробнее

PARP Inhibitors in 2020: Where Are We Now, and Where Are We Going | Webinar | Ambry GeneticsПодробнее

Niraparib Shows Positive Data, Requires Different Dosing in Ovarian CancerПодробнее

Personalizing Advanced Ovarian Cancer Treatment With PARP Inhibitors and Novel ApproachesПодробнее

FDA D.I.S.C.O.: Niraparib in Ovarian Cancer TranscriptПодробнее

Is It Time to Change Upfront Chemotherapy for Ovarian Cancer?Подробнее

2019 SGO 50th Annual Meeting: Opening Scientific PlenaryПодробнее

PARP inhibitors: game-changers for ovarian cancer patients?Подробнее

Results of Niraparib/Bevacizumab Combo in Platinum-Sensitive Recurrent Ovarian CancerПодробнее

Combination therapy to treat ovarian cancer: promising results from the ANANOVA trialПодробнее

Dr. Mirza on Efficacy of Niraparib/Bevacizumab Combo in Recurrent Ovarian CancerПодробнее

Niraparib Maintenance for Recurrent Ovarian CancerПодробнее

Dr. Mirza Discusses Niraparib Dose Modifications for Ovarian Cancer Patients With Low Body WeightПодробнее

Long-term safety of niraparib maintenance treatment in patients with recurrent ovarian cancerПодробнее

Ovarian Cancer: Optimizing Treatment With NiraparibПодробнее